​“Developing novel therapies to reduce human suffering and improve patient quality of life are greatly gratifying. Creating novel therapies to treat unmet medical needs is particularly satisfying. At EndoProtech, we strive to serve our patients by developing highly effective therapeutic solutions at affordable cost.”
– Claudio Maldonado, PhD, President and CEO
​
​“Research is one of my great passions in life. I aspire to share my knowledge, talent and vision, to develop and transfer therapies from the “bench to the bedside”. EndoProtech has given me this wonderful opportunity to realize my dream. Our team works diligently to develop innovative therapies that will wholly impact patient’s quality of life.”
– Mai-Dung Nguyen, PhD, Senior Research Associate
Executive Board Member
Founded in 2004, Endoprotech is the vision of Claudio Maldonado Ph.D., Gustavo Perez-Abadia MD, and Federico Grossi, MD/Ph.D. Their goal remains to improve patient quality of life through unique liposomal-based pharmaceutical delivery systems..
Claudio Maldonado, PhD
Founder, President and CEO
Dr. Maldonado’s general research interests are in cardiovascular research and transplantation of composite vascularized allographs. He has a Physiology Ph.D. degree and is a tenured Professor in the Physiology Department at the University of Louisville. Dr. Maldonado was a member of the research team that performed pre-clinical studies that eventually led to clinical hand and face transplantation. Dr. Maldonado’s translational research efforts have focused on novel applications of liposome delivery systems to reduce inflammation in transplantation, myocardial infarction and alcoholic liver disease (ALD). His research has focused on developing novel therapies that protect the endothelium from ischemia/reperfusion injury. Dr. Maldonado has developed novel liposome based technologies that rapidly modify the surface of the endothelium to stabilize barrier function to mitigate ischemia/reperfusion iatrogenic injury. In addition, he has developed liposomal formulations that target the liver to deliver anti-inflammatory inhibitors to treat ALD with reduced side-effects. Dr. Maldonado is co-inventor of three awarded or pending patents. He has served as the company’s CEO since 2004.
Gustavo Perez-Abadia, MD
Founder, Vice President, and Treasurer
Dr. Perez-Abadia’s general research interest are in microsurgery, preservation of organs/tissues for transplantation, and composite vascular allotransplantation. He received his medical degree in medicine from the Universidad Nacional de Tucuman, Tucuman city, Argentina. He trained as a Pediatric Surgeon in Cordoba, Argentina. Dr. Pérez-Abadía was a member of the research team that performed key pre-clinical studies that eventually led to the first successful hand transplant in the world. He is currently the Director/Instructor of the internationally renowned Microsurgery Teaching Course at the University of Louisville. He is an Assistant Professor in the Department of Orthopedic Surgery at the University of Louisville. He has trained hundreds of surgeons and researches while teaching in the Departments of Surgery, Physiology, and Orthopedics at the University of Louisville. Also, he has trained fellows from the Kleinert & Kutz Hand Care Center for over 20 years. He teaches microsurgery in “sister microlaboratories” in 8 countries in the continents of Europe, and in North- and South-America. He was instrumental in the development of pre-clinical models of organ transplantation and ischemia/reperfusion injury to test efficacy of various liposome lipid formulations. As treasurer he has streamlined the company’s procurement of supplies, reagents and equipment.
Federico Grossi, MD/PhD
Founder
Dr. Grossi has held positions at Potentia Pharmaceuticals and Apellis Pharmaceuticals as Clinical Research Director. He currently is the Executive Vice President of Clinical Development and Medical Affairs for Apellis. Dr. Grossi received his medical degree from the University of Cordoba in Argentina and his Doctorate’s Degree in Physiology from the University of Louisville. Following his post graduate training in surgery, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville where he developed his expertise in microsurgery and transplantation of composite tissues. He was a contributing member of the Louisville Face Transplant Team, which has published extensively on the ethical and psychological aspects of face transplantation that are now considered hallmark publications in this field. He has also published numerous articles in the fields of ischemic preconditioning and composite vascular allotransplantation.
Philip Bauer, PhD
Board Secretary and Senior Scientist
Dr. Bauer’s general research interests are in the development of liposomes for medicinal applications in cardiovascular disease and transplantation of composite vascularized allographs. He has a Ph.D. degree in Chemistry from the University of Louisville and has a gratis Adjunct Professor appointment in the Department of Physiology at the University of Louisville. As a research scientist at EndoProtech, Inc., Dr. Bauer has developed and optimized the lipid formulation of a therapy to treat reperfusion injury following stent placement in patients suffering myocardial infarction. Also, Dr. Bauer has optimized the liposomal formulation for the delivery of a phosphodiesterase inhibitor for treatment of alcoholic liver disease. Dr. Bauer is current Project Director on a Phase II/NHLBI grant award, and has served as Project Director on three completed NIH Phase I (NHLBI) and Phase I and II (NIAAA) grant awards. Dr. Bauer has been an employee of EndoProtech Inc. for 10 years, and is co-inventor of two company pending patents.